HC-7366, our second adaptive stress product candidate, is a differentiated selective, orally bioavailable modulator of a key stress response protein kinase, GCN2.  HC-7366 is under investigation in a Phase 1a/b trial as monotherapy for treatment of advanced solid tumors including, head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), transitional cell carcinoma of the bladder, and other solid tumors.  We have initiated the Phase 1b portion of our solid tumor study in RCC and plan to initiate additional Phase 1b combination studies renal cell carcinoma (RCC) and in acute myeloid leukemia (AML).

HC-5404, our first adaptive stress product candidate, is a differentiated highly selective, orally bioavailable inhibitor of a key stress response protein kinase, PERK.  HC-5404 recently completed investigation in a Phase 1a trial as a monotherapy for the treatment of advanced solid tumors enriched for patients with renal cell carcinoma (RCC) and gastric cancer.  Following the completion of our Phase 1a trial, we are now seeking partners for a Phase 1b trial in combination with VEGFR TKIs in multiple solid tumors.

Odetiglucan (Imprime PGG) is our systemically administered innate and adaptive immune modulator therapeutic candidate.  Odetiglucan has also demonstrated increased response rates and disease control rates in patients with liver metastasis across varied tumor histologies, with multiple therapeutic classes. Odetiglucan will be evaluated in a Phase 2 investigator initiated clinical trial further exploring this mechanism in combination with an immune checkpoint inhibitor in patients with colorectal cancer liver metastasis.